Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer

References

• Carmo-Pereira J, Costa F, Henriques E, Godinho F, Cantinho-Lopes M, Sales-Luis A, et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987; 56: 471–3
   PubMed Web of Science ®Google Scholar
• French-epirubicin-study-group. Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment. J Clin Oncol 2000;18:3115–24.
   PubMed Web of Science ®Google Scholar
• Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377–87
   PubMed Web of Science ®Google Scholar
• Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439–60
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7–16
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000; 342: 1069–76
   PubMed Web of Science ®Google Scholar
• Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002; 86: 1297–302
   PubMed Web of Science ®Google Scholar
• Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, Gjedde SB, et al. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 1991; 28: 465–9
   PubMed Web of Science ®Google Scholar
• Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003; 89: 1837–42
   PubMed Web of Science ®Google Scholar
• Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999; 80: 1763–6
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997; 75: 301–5
   PubMed Web of Science ®Google Scholar
• Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001; 91: 2246–57
   PubMed Web of Science ®Google Scholar
• Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356(9239)1384–91
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R. Quality of life assessment in clinical trials--guidelines and a checklist for protocol writers: The U.K. Medical Research Council experience. MRC Cancer Trials Office. Eur J Cancer 1997; 33: 20–8
   PubMed Web of Science ®Google Scholar
• Jakobsen P, Steiness E, Bastholt L, Dalmark M, Lorenzen A, Petersen D, et al. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: Studies in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1991; 28: 63–8
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Freijs A, Larsson R, Nygren P, Fjallskog ML, Bergh J, et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996; 14: 1581–8
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 2006; 58: 143–56
   PubMed Web of Science ®Google Scholar
• Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson N-O, Malmström P, et al. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity to high-risk breast cancer patients. Ann Oncol 1998; 9: 403–11
   PubMed Web of Science ®Google Scholar
• Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 2005; 23: 5117–25
   PubMed Web of Science ®Google Scholar
• Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989; 60: 121–5
   PubMed Web of Science ®Google Scholar
• Ferguson JE, Dodwell DJ, Seymour AM, Richards MA, Howell A. High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. Br J Cancer 1993; 67: 825–9
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bruning P, Wildiers J, Awada A, Schornagel JH, Thomas J, et al. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer. Ann Oncol 1995; 6: 673–7
   PubMed Web of Science ®Google Scholar
• Van Hoef ME, Baumann I, Lange C, Luft T, de Wynter EA, Ranson M, et al. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy. Ann Oncol 1994; 5: 217–24
   PubMed Web of Science ®Google Scholar